AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02828878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic MPBC transplantation from matched related donor
Study NCT00960063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study NCT00960063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Study NCT00355485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microdermabrasion
Description: Device: Bellamed microdermabrasion system produced by Bella products or the Altair Diamondtome System.~Subjects will receive a series of microdermabrasion treatment sessions (up to 6) spaced one to two weeks apart.
Study NCT00960063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT00960063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Robatumumab
Study NCT00960063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT00960063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT01391039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren lipid microsphere
Description: Intravenous injection of 10 microL/kg once prior to ultrasound examination
Study NCT04281446 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Photobiomodulation
Description: Application of light at specific wavelength for interaction with biological tissue
Study NCT00960063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT04274816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Intradermal injection of tremelimumab 7 days prior to sentinel node biopsy, with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).
Study NCT03865446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: anti-cancer agent
Study NCT00976131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CoQ10
Description: Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d CoQ10 (2 capsules) Dose Level 2: 600mg/d CoQ10 (4 capsules) Dose Level 3: 1200mg/d CoQ10 (8 capsules)
Study NCT00976131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoQ10
Description: Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d CoQ10 (2 capsules) Dose Level 2: 600mg/d CoQ10 (4 capsules) Dose Level 3: 1200mg/d CoQ10 (8 capsules)
Study NCT00976131 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CoQ10 Placebo
Description: Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d placebo (2 capsules) Dose Level 2: 600mg/d placebo (4 capsules) Dose Level 3: 1200mg/d placebo (8 capsules)
Study NCT00976131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoQ10 Placebo
Description: Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d placebo (2 capsules) Dose Level 2: 600mg/d placebo (4 capsules) Dose Level 3: 1200mg/d placebo (8 capsules)
Study NCT00976131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Standard of care chemotherapy medication used to treat cancer.
Study NCT00976131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Standard of care chemotherapy medication used to treat cancer.
Study NCT00976131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Standard of care chemotherapy medication used to treat cancer.
Study NCT04281446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Application of light at specific wavelength for interaction with biological tissue
Study NCT00311727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H5N1
Description: 232 subjects receive Influenza A/H5N1 vaccine as part of DMID protocols 04-063 and 04-076.
Study NCT02523599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XaraColl
Description: Surgical implantation of 3 bupivacaine collagen implants
Study NCT02523599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Plain collagen implant (vehicle)
Study NCT01427751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone intravitreal implant
Description: Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
Study NCT01427751 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
Study NCT01864954 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web+phone
Description: We propose to evaluate the feasibility, acceptability, and efficacy of a Web+phone treatment program in a small, randomized, controlled pilot study. Women who have quit smoking during pregnancy will be randomly assigned to either (a) an Enhanced Web+phone intervention or (b) a Basic Web Information-Only control condition.
Study NCT01864954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web+phone
Description: We propose to evaluate the feasibility, acceptability, and efficacy of a Web+phone treatment program in a small, randomized, controlled pilot study. Women who have quit smoking during pregnancy will be randomly assigned to either (a) an Enhanced Web+phone intervention or (b) a Basic Web Information-Only control condition.
Study NCT00531102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure
Description: Infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes
Study NCT00531102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free flow oxygen
Description: Infants will receive 50% oxygen delivered by a modified neonatal T-piece resuscitator circuit that does not generate pressure for at least 5 minutes.
Study NCT04208282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7 day infusion set
Description: 7 days survival of the sets
Study NCT04208282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 7 day infusion set
Description: 7 days survival of the sets
Study NCT04328454 — intervention group
Intervention type: OTHER
Intervention: retrospective analysis
Description: The investigators retrospectively analyzed the hospitalized patients with COVID-19
Study NCT04640077 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: No intervention
Study NCT04640077 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: donanemab
Description: Administered IV
Study NCT03689660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training
Description: Participants will be given a game-based workout program that includes balance and weight transfers using the XBOX Kinect ™ device in a low-to-medium intensity for 3 weeks, 3 days a week, 30 minutes per day.
Study NCT03689660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback Training
Description: biofeedback training will be applied to participants in 10-minute sessions with 10 seconds of voluntary contraction and 15 seconds of rest at each session. Training will last 12 weeks.
Study NCT03689660 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional rehabilitation
Description: Participants will receive a 12-week conventional rehabilitation program.
Study NCT00976131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Standard of care chemotherapy medication used to treat cancer.
Study NCT03805802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active product
Description: Once daily consumption over the period of the study
Study NCT03805802 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: active product
Description: Once daily consumption over the period of the study
Study NCT03805802 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: reference product
Description: Once daily consumption over the period of the study
Study NCT06402396 — intervention group
Intervention type: DRUG
Intervention: bDMARDS
Description: Patients at time of the PDQ assessment and up to 4 months thereafter being on ongoing bDMARDs treatment or on switch of bDMARD treatment.
Study NCT01497600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
Study NCT02729220 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bronchoscopy
Description: Sampling of airways
Study NCT05313113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. The training content included topics such as setting a comfortable environment and suitable position for the pregnant, when the fetus is active and asleep during the day, how to count and how to evaluate the movements. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
Study NCT01497600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
Study NCT01497600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
Study NCT01173016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laronidase
Description: Laronidase 0.58 mg/kg intravenously (IV) once a week for a maximum of 2 years
Study NCT01068522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parenchymal Intracranial pressure monitor
Description: Treatment based on readings from Parenchymal intracranial pressure monitor.
Study NCT01068522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment based on clinical and imaging observations
Description: Treatment based on clinical and imaging observations.
Study NCT01425801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS100977 0.313 μg
Description: Dry powder inhalation, once-daily, single-dose
Study NCT01425801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS100977 0.625 μg
Description: Dry powder inhalation, once-daily, single-dose
Study NCT01425801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS100977 1.25 μg
Description: Dry powder inhalation, once-daily, single-dose
Study NCT01425801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS100977 2.5 μg
Description: Dry powder inhalation, once-daily, single-dose
Study NCT01425801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol 400 μg
Description: Pressurized inhalation suspension, once-daily, single-dose
Study NCT01425801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol placebo
Description: Pressurized inhalation, once-daily
Study NCT01425801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol placebo
Description: Pressurized inhalation, once-daily
Study NCT01425801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAS100977 placebo
Description: Dry powder inhalation, once-daily
Study NCT01425801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS100977 placebo
Description: Dry powder inhalation, once-daily
Study NCT02946281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Do CHANGE
Description: The intervention aims to increase behavioral flexibility and change patients' (unhealthy) lifestyle. At the same time the intervention should increase patient self-management and improve the patient reported outcomes (e.g. quality of life, anxiety, depression).
Study NCT01442480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Subjects (ages 50 to 75 years), were randomly assigned to receive 3 g/d of fish oil (1.2 g eicosapentaenoic acid and 0.82 g docosahexaenoic acid) for 28 d.
Study NCT01442480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: Subjects (ages 50 to 75 years) were randomly assigned to receive 3 g/d of olive oil for 28 d.
Study NCT04040374 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AI-based diagnosis
Description: AI-based diagnosis will be performed based on analysis of endoscopic images (Olympus Optical, Tokyo, Japan). The investigators will use the Single Shot MultiBox Detector (SSD), a deep neural network architecture (https://arxiv.org/abs/1512.02325), and an optimal diagnostic cutoff from a prior report2. The AI system reviewed endoscopy images and reported those in which gastric cancer was detected, together with the coordinates (X, Y) of the lesions.
Study NCT04040374 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: The expert endoscopists-based diagnosis
Description: The expert endoscopists are two physicians with experience of more than 20,000 endoscopies. The expert endoscopists will review the endoscopy images of each patient for 5 min. They will then report endoscopy images in which gastric cancer was detected and manually annotate the lesions in those images.
Study NCT05329844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin 50 MG
Description: 50 mg Vildagliptin as single-dose per study period
Study NCT01497600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin NPH
Description: Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
Study NCT02545933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
Study NCT02545933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
Study NCT05329844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 MG
Description: 50 mg Vildagliptin as single-dose per study period
Study NCT04213547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss frame sleep extension intervention
Description: Aim 2 will be an interventional study design utilizing Fitbit and text messaging to perform a loss-framed incentive intervention designed to motivate participants to increase their sleep duration. Glycemic control will be measured via laboratory testing of hemoglobin A1c and Libre continuous glucose monitoring (CGM) for 2 weeks pre- and post-intervention. A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging.
Study NCT01071681 — intervention group
Intervention type: DRUG
Intervention: Telmisartan (Kinzal/Pritor, BAY68-9291)
Description: Patients under daily life treatment receiving Pritor according to local drug information.
Study NCT00990106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prazosin hydrochloride
Description: Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) then titrating the dose upward gradually.
Study NCT00990106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02138890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APS
Description: Intra-articular Injection
Study NCT02138890 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intra-articular injection
Study NCT03144739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in management of children's mental health problems
Description: General practitioners will be trained using internationally-developed materials, including the World Health Organization's mental health need/service gap (mhGAP) materials and others, adapted for the trial setting (based on formative work that is part of the project). They will be assisted and monitored as part of the ongoing collaborative care program in which they are participating.
Study NCT03144739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current collaborative care protocol
Description: General practitioners have been trained to recognize children's mental health problems and to refer them to a partner community mental health center. They receive feedback about the referral but are not encouraged to take on care for the child themselves.
Study NCT02892994 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound
Study NCT02892994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound
Study NCT01307826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: session - 20 minutes.~Before the massage, palpable evaluation of the selected anatomical structures was carried out - to determine which tissues have the greatest sensitivity and which motor organs show increased tension (by pressing the attachment). In all the examined patients, pain of the following muscle attachments were shown:~* latissimus muscle of the back~* major pectoral muscle~* supraspinous and infraspinous muscles~* teres minor muscle~* serratus anterior muscle~* deltoid muscle The decision which muscles and fascias have to be massaged was made on the basis of the performed evaluation. In most cases the above mentioned tissues (together with other motor system organs which are structurally linked to it) were massaged to relax them.~A palpable evaluation of the previously examined points was again performed during the final part, with particular attention paid to painful muscles, in order to analyze the effectiveness of the performed relaxation.
Study NCT01307826 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: massage
Description: classical massage (Swedish massage)
Study NCT03826940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin 60 MG
Description: 60 MG Lovastatin per day for 3 consecutive days
Study NCT03826940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 60 MG Placebo per day for 3 consecutive days
Study NCT00685165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primidone 50 mg Tablet
Description: 50 mg tablet administered after an overnight fast of at least 10 hours.
Study NCT00685165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primidone (Mysoline®) 50 mg Tablet
Description: 50 mg tablet administered after an overnight fast of at least 10 hours.
Study NCT03890185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemo alone
Description: Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
Study NCT02545933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Description: Vorapaxar will be administered at the dose of 2.5mg once daily
Study NCT02545933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin will be administered at the dose of 81mg once daily
Study NCT02545933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin will be administered at the dose of 81mg once daily
Study NCT02545933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
Study NCT02545933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
Study NCT03417895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A humanized anti-PD-1 monoclonal antibody
Study NCT03417895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: A tyrosine kinase inhibitor selectively targeting VEGFR-2